Keywords: Novartis, Lucentis, Diabetic macular edema, UK, NICE, DME, DMO

UK's NICE backs use of Novartis' Lucentis for diabetic macular edema

Article | 27 February 2013

Print This

Reversing an earlier negative opinion, in a final guidance issued today (February 27), the UK drugs watchdog the National Institute for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in